news
Daiichi Sankyo receives approval for the use of Inavir® to prevent influenza
20 December 2013 | By Daiichi Sankyo
Inavir® is a long-acting neuraminidase inhibitor developed by Daiichi Sankyo which is manufactured in Japan...
List view / Grid view
Daiichi Sankyo
news
Daiichi Sankyo submits supplemental New Drug Application in Japan for LIXIANA® (Edoxaban Tosilate Hydrate) for new indications
19 December 2013 | By Daiichi Sankyo Company
Daiichi Sankyo is seeking approval in Japan for edoxaban in new indications for non-valvular atrial fibrillation (AF) and symptomatic venous thromboembolism...
news
Daiichi Sankyo launches four new generic drugs through its Daiichi Sankyo Espha Subsidiary
13 December 2013 | By Daiichi Sankyo
Daiichi Sankyo Espha launched two new generic drugs with two new active ingredients and two generic drugs with an additional standard...
news
Phase 3 data show Daiichi Sankyo’s once-daily edoxaban lowered incidence of VTE recurrence and clinically relevant bleeding
10 December 2013 | By Daiichi Sankyo Company
This analysis of VTE patients with cancer was presented at the 2013 American Society of Hematology Annual Meeting and Exposition...
news
Daiichi Sankyo launches natural tetrahydrobiopterin agent Biopten® Granules 10%
29 November 2013 | By Daiichi Sankyo Company,
Biopten is a highly pure, chemically synthesized form of natural tetrahydrobiopterin (hereafter, BH4) that occurs naturally in the human body...
news
Daiichi Sankyo’s once-daily edoxaban meets primary efficacy endpoint for stroke prevention and superiority for the principal safety endpoint compared to Warfarin for patients with atrial fibrillation in a phase 3 clinical trial
20 November 2013 | By Daiichi Sankyo Europe
Once-daily edoxaban, evaluated in two treatment arms achieved the primary endpoint of non-inferior efficacy versus warfarin in the prevention of stroke or systemic embolism...
news
Daiichi Sankyo selects research partners for TaNeDS Collaborative Drug Discovery project
23 October 2013 | By Daiichi Sankyo Company
The researchers were selected from universities and public research centers in Japan...
news
AstraZeneca and Daiichi Sankyo announce iPhone app for reflux esophagitis
18 September 2013 | By
Daiichi Sankyo Co., Ltd. and AstraZeneca K.K. are working to educate the public about reflux esophagitis through a campaign entitled “Do you experience heartburn or acid reflux?”
news
Daiichi Sankyo’s once-daily edoxaban shows comparable efficacy and superiority for the principal safety endpoint compared to warfarin in a Phase 3 study for the treatment of symptomatic VTE and prevention of its recurrence
1 September 2013 | By Daiichi Sankyo
Daiichi Sankyo announced results from the global phase 3 Hokusai-VTE study...
news
Daiichi Sankyo submits application to manufacture and market RANMARK® for treatment of giant cell tumor of bone in Japan
29 August 2013 | By Daiichi Sankyo
Daiichi Sankyo has filed an application for approval in Japan to manufacture and market RANMARK®...
news
Daiichi Sankyo to Expand Its Collaborative Drug Discovery Program to Germany, Switzerland, and Austria
29 July 2013 | By Daiichi Sankyo
Daiichi Sankyo announced that it will expand its Take a New challenge for Drug diScovery Global Program...
news
Daiichi Sankyo announces Phase 3 study results (PRASFIT-Elective study) for the antiplatelet agent prasugrel in Japan
12 July 2013 | By Daiichi Sankyo
Results of a phase 3 clinical study...
news
Daiichi Sankyo submits a New Drug Application in Japan for the antiplatelet agent prasugrel
18 June 2013 | By Daiichi Sankyo
The application is based on the results of a phase 3 trial...
news
Perosphere and Daiichi Sankyo enter into a clinical trial agreement
26 April 2013 | By Daiichi Sankyo
Daiichi Sankyo to support and co-sponsor phase 1 Clinical Study...
news
Daiichi Sankyo enrolls first patient in Nimotuzumab Phase 3 clinical trials
25 April 2013 | By Daiichi Sankyo
The first patient has been enrolled in two pivotal phase 3 clinical trials of nimotuzumab...
